FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors



Merck Sharp & Dohme Corp.

Nano-suspension process

Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
22012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
32014027501709/18/14Cgrp receptor antagonists
42014025681809/11/14Nano-suspension process
52014024428908/28/14Cold storage system for storing pharmaceutical product containers
62014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
72014023430108/21/14Modulation of pilr to treat immune disorders
82014023553708/21/14N-glycosylated insulin analogues
92014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
102014022722308/14/14Pegylated interleukin-10
112014022725008/14/14Stable formulations of antibodies to tslp
122014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
132014022729208/14/14Anti-mcam antibodies and associated methods of use
142014022002708/07/141d05 pcsk9 antagonists
152014022138308/07/14Cetp inhibitors
162014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
172014020656307/24/14Biomarkers for psoriasis
182014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
192014020664107/24/14Remedy
202014020666507/24/14Selective glycosidase inhibitors and uses thereof
212014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
222014020671507/24/14Preparation and use of compounds as protease inhibitors
232014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
242014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
252014017015406/19/14Engineered anti-il-23r antibodies
262014017065806/19/14Mammalian cytokines; related reagents
272014017143706/19/14Oxazole derivatives useful as inhibitors of faah
282014017145606/19/14Fused tricyclic compounds as mtor inhibitors
292014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
302014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
312014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
322014014744205/29/14Use of il-23 antagonists for treatment of infection
332014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
342014014095405/22/14Methods of modulating cytokine activity; related reagents
352014014101205/22/14Engineered anti-tslp antibody
362014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
372014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
382014014211505/22/14Inhibitors of the renal outer medullary potassium channel
392014014095405/22/14Methods of modulating cytokine activity; related reagents
402014014101205/22/14Engineered anti-tslp antibody
412014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
422014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
432014014211505/22/14Inhibitors of the renal outer medullary potassium channel
442014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
452014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
462014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
472014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
482014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
492014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
502014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
512014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
522014011291904/24/14Interleukin-10 antibodies
532014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
542014011291904/24/14Interleukin-10 antibodies
552014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
562014010588704/17/14Methods for modulating il-33 activity
572014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
582014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
592014010588704/17/14Methods for modulating il-33 activity
602014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
612014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
622014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
632014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
642014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
652014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
662014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
672014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
682014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
692014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
702014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
712014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
722014004574602/13/14Antidiabetic tricyclic compounds
732014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
742014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
752014003762702/06/14Modulation of pilr receptors to treat microbial infections
762014003894202/06/14Rorgammat inhibitors
772014003897002/06/14Bridged and fused antidiabetic compounds
782014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
792014003076001/30/14Pavec
802014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
812014003134901/30/14Inhibitors of the renal outer medullary potassium channel
822014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
832014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
842013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
852013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
862013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
872013032323912/05/13Modulation of pilr receptors to treat sepsis
882013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
892013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
902013032448312/05/13Mammalian cell surface antigens; related reagents
912013032461012/05/13Cathepsin cysteine protease inhibitors
922013032472812/05/13Process for the preparation of an orexin receptor antagonist
932013031635411/28/13Mammalian cytokine; related reagents
942013029627811/07/13Diazeniumdiolate derivatives
952013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
962013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
972013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
982013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
992013025167709/26/13Genetic markers associated with interferon-alpha response
1002013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
1012013023751809/12/13Novel compounds that are erk inhibitors
1022013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
1032013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1042013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1052013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1062013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1072013021657508/22/13Recombinant subunit dengue virus vaccine
1082013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1092013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1102013021776608/22/13Formulations for cathepsin k inhibitors
1112013021657508/22/13Recombinant subunit dengue virus vaccine
1122013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1132013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1142013021776608/22/13Formulations for cathepsin k inhibitors
1152013020306008/08/13Mammalian genes; related reagents
1162013020306008/08/13Mammalian genes; related reagents
1172013018927807/25/13Antagonists of pcsk9
1182013018927807/25/13Antagonists of pcsk9
1192013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1202013015672906/20/13Mammalian receptor proteins; related reagents and methods
1212013015677106/20/13Fdf03 antibodies and uses thereof
1222013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1232013015672906/20/13Mammalian receptor proteins; related reagents and methods
1242013015677106/20/13Fdf03 antibodies and uses thereof
1252013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1262013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1272013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1282013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1292013013104105/23/13Spirocyclic compounds
1302013013104205/23/13Spiroxazolidinone compounds
1312013013104105/23/13Spirocyclic compounds
1322013013104205/23/13Spiroxazolidinone compounds
1332013012200905/16/13Engineered anti-il-23p19 antibodies
1342013012320005/16/13Mammalian cell surface antigens; related reagents
1352013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1362013012200905/16/13Engineered anti-il-23p19 antibodies
1372013012320005/16/13Mammalian cell surface antigens; related reagents
1382013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1392013011522305/09/13Antagonists of pcsk9
1402013011623105/09/13Tyrosine kinase inhibitors
1412013011522305/09/13Antagonists of pcsk9
1422013011623105/09/13Tyrosine kinase inhibitors
1432013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1442013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1452013007139003/21/13Method for preparing antibodies having improved properties
1462013006481703/14/13Engineered anti-il-23r antibodies
1472013005985003/07/13Aza-indole derivatives useful as modulators of faah
1482013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1492013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1502013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1512013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1522013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1532013003531202/07/13Cathepsin cysteine protease inhibiors
1542013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1552013001804801/17/13Oxazole derivatives useful as modulators of faah
1562013001252601/10/13Oxazole derivatives useful as modulators of faah
1572013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1582013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1592012032967912/27/12Eukaryotic cell display systems
1602012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1612012031620012/13/12Pyridone derivatives
1622012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1632012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1642012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1652012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1662012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1672012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1682012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1692012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1702012019690108/02/12Tertiary amide orexin receptor antagonists
1712012019070107/26/12Renin inhibitors
1722012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1732012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1742012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1752012016415806/28/12Anti-addl monoclonal antibody and use thereof
1762012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1772012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1782012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
1792012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
1802012014275206/07/12Hiv protease inhibitors
1812012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
1822012012162405/17/12Hepatitis c virus ns3 protease inhibitors
1832012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
1842012012150805/17/12Radiolabeled cgrp antagonists
1852012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
1862012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1872012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1882012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1892012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
1902012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
1912012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
1922012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
1932012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1942012008348304/05/12Inhibitors of hepatitis c virus replication
1952012008267904/05/12Antagonists of pcsk9
1962012008268004/05/12Antagonists of pcsk9
1972012007679903/29/12Antagonists of pcsk9
1982012007796403/29/12Antagonists of pcsk9
1992012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
2002012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
2012012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
2022012003521402/09/12Renin inhibitors
2032012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
2042012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
2052012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
2062012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
2072012002107401/26/12P2x3, receptor antagonists for treatment of pain
2082012002194801/26/12Surface display of whole antibodies in eukaryotes
2092012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
2102012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
2112012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
2122012000958001/12/12Methods for quantitating small rna molecules
2132012001019301/12/12Cgrp receptor antagonists
2142012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2152012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2162012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2172012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2182011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2192011030107912/08/11Neuromedin u receptor agonists and uses thereof
2202011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
2212011029473512/01/11Mechanism of neuromedin u action and uses thereof
2222011029477712/01/11Beta-lactamase inhibitors
2232011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2242011025059110/13/11Method of designing sirnas for gene silencing
2252011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2262011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2272011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2282011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus
2292011023049809/22/11Biaryl carboxamides
2302011023052609/22/11Thiazolyl mglur5 antagonists and methods for their use
2312011022419309/15/11Inhibitors of diacylglycerol acyltransferase
2322011022413409/15/11Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
2332011022419509/15/11Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
2342011021817409/08/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2352011021820209/08/11Soluble guanylate cyclase activators
2362011020773708/25/11Substituted bicyclic amines for the treatment of diabetes
2372011020794208/25/11Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole
2382011020162108/18/11Angiotensin ii receptor antagonists
2392011019595708/11/11Substituted diazepan orexin receptor antagonists
2402011019030808/04/11Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2412011019034608/04/11Diphenyl substituted alkanes as flap inhibitors
2422011017805907/21/111,3-oxazolidin -2-one derivatives useful as cetp inhibitors
2432011017811707/21/11Oxazolobenzimidazole derivatives
2442011017881907/21/11Devices and methods for determining a patient's propensity to adhere to a medication prescription
2452011017220507/14/11Monocyclic amide cgrp receptor antagonists
2462011015230406/23/11Spiroazaindoles
2472011013676906/09/11Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
2482011012466105/26/11Oxazolobenzimidazole derivatives
2492011011833705/19/11Method of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo